Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Invivyd, Inc.IVVD · Entity 721 | CMO and Chief Epidemiologist | July 31, 2026 | August 04, 2026 |
| Quantum-Si IncQSI · Entity 6440 | Director | May 12, 2023 | May 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Invivyd, Inc.
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2036-07-30 | Direct | 1,125,000 |
Reported balance
After 2026-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 1,125,000 · Balance 1,125,000 F1: This option vests over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date of July 31, 2026 and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date of July 31, 2026 and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.
Quantum-Si Inc
Report date May 12, 2023 · Filed May 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2033-05-12 | Direct | 120,481 |
Reported balance
After 2023-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-12 · Grant · Acquired 120,481 · Balance 120,481 F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Dr. Mina's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Dr. Mina's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 20:15 UTC | Invivyd, Inc. IVVD · Entity 721 | GrantStock Option (Right to Buy) · Derivative | 1,125,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001193125-26-332844 · ownership.xml · derivative · entry 1 Mina Michael · CIK 0001856954 · CMO and Chief Epidemiologist 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,125,000 Underlying: Common Stock · 1,125,000 shares Expires 2036-07-30 F1 · derivative.exercise_date: This option vests over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date of July 31, 2026 and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:57 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 120,481 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001140361-23-025057 · form4.xml · derivative · entry 1 Mina Michael · CIK 0001856954 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,481 Underlying: Class A Common Stock · 120,481 shares Expires 2033-05-12 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Dr. Mina's continued service through the applicable vesting date. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:18 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 59,880 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001140361-22-019087 · form4.xml · derivative · entry 1 Mina Michael · CIK 0001856954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,880 Underlying: Class A Common Stock · 59,880 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Dr. Mina's continued service through the applicable vesting date. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 22:54 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantClass A Common Stock | 20,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-080930 · tm2119549-21_4seq1.xml · nonDerivative · entry 1 Mina Michael · CIK 0001856954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,512 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on June 11, 2022, subject to Dr. Mina's continued service through the applicable vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:54 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantClass A Common Stock · Derivative | 358,875 | Not disclosed Strike: $9.46 | Not disclosed |
DisclosureSEC source: 0001104659-21-080930 · tm2119549-21_4seq1.xml · derivative · entry 2 Mina Michael · CIK 0001856954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,875 Underlying: Class A Common Stock · 358,875 shares Expires 2031-04-20 F3 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of February 18, 2021, by and among HighCape Capital Acquisition Corp. ("HighCape"), Tenet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HighCape ("Merger Sub"), and Quantum-Si Incorporated, a Delaware corporation ("Quantum-Si"), pursuant to which Merger Sub merged with and into Quantum-Si (the "Merger"), with Quantum-Si surviving as a wholly-owned subsidiary of HighCape (which changed its name to "Quantum-Si Incorporated", the "Issuer"), these shares were received in exchange for a stock option to acquire 450,000 shares of Qunatum-Si common stock for $7.54 per share. F2 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments over 36 months beginning on May 31, 2021, subject to Dr. Mina's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.